Resistance to TGF-b1 occurred in pancreatic cancer cells suggesting that inactivation of TGF-b inhibitory signaling pathways may play an important role in human pancreatic cancer. The aim of our study was to determine the presence of alterations in the main putative components of the TGF-b inhibitory signaling pathways (p15, Smad4, Smad2, TGFb-RII, CDC25A). A panel of human carcinomas of the exocrine pancreas orthotopically implanted and perpetuated in nude mice and pancreatic cancer cell lines were studied. p15 gene alterations, mainly homozygous deletions that involved exons 1 and/or 2, were found in the 62.5% (5 of 8) of pancreatic xenografts whereas Smad4 gene aberrations were found in one of eight xenografts and in two of seven cell lines. Additional aberrations in these genes were acquired during in vivo perpetuation and distal dissemination. Paradoxically, TGFb-RII overexpression and a decrease in CDC25A protein levels were found in all tumors and cell lines. In one cell line, resistance to TGFb1 occurred in the absence of alterations in the genes analysed so far. We conclude that all human pancreatic tumor cells analysed herein have non-functional TGF-b pathways. The majority of cells harbor alterations in at least one of the putative components of TGF-b pathways, mainly in p15 and Smad4 genes. These results suggest that inactivation of TGF-b signaling pathways plays an important role in human pancreatic tumorigenesis.
Introduction
TGF-b mediates growth inhibitory signals in dierent cell types. It acts as an adapter that binds and brings together members of two subfamilies of transmembrane serine/threonine kinases named TGF-b type I and type II receptors (MassagueÂ , 1996) . In the resulting complex the type II receptor phosphorylates the type I, which then propagates the signal (Ebner et al., 1993; Wrana et al., 1994) . SMAD2, a member of the recently identi®ed SMAD protein family, has been proposed to be directly phosphorylated by the activated TGF-b receptors (Liu et al., 1996; MaciasSilva et al., 1996; Nakao et al., 1997) . Upon phosphorylation, SMAD2 binds to SMAD4 (Lagna et al., 1996) , which plays a central role as the shared hetero-oligomerization partner of the other SMAD proteins (Shi et al., 1997) . These speci®c complexes translocate to the nucleus (Macias-Silva et al., 1996; Nakao et al., 1997; Lagna et al., 1996; Eppert et al., 1996) , where they become associated with DNA binding proteins such as Fast-1, and regulate transcription (Chen et al., 1996) .
TGF-b1 inhibits growth by causing cell cycle arrest after increasing the concentration of the CDK4/6 inhibitor P15 (Hannon and Beach, 1994) . The association of P15 to Cyclin D1-CDK4/6 complexes releases P27 that subsequently binds to, and inhibits Cyclin A-CDK2 complexes (ReynisdoÂ ttir and MassagueÂ , 1997). Thus, it has been suggested that P15 expression would be under the transcriptional control of SMAD2/4 complexes formed after the activation of TGF-b receptors (Macias-Silva et al., 1996; Nakao et al., 1997; Lagna et al., 1996) . Until now, no other extracellular signals have been shown to modify p15 levels. Recently, it has been described that TGF-b can also cause inhibition of CDK4/6 activities by increasing their level of tyrosine phosphorylation. Tyrosine phosphorylation and inactivation of CDK4/6 result from the ability of TGF-b1 to inhibit the expression of CDC25A, a CDK tyrosine phosphatase (Galaktionov and Beach, 1991; Galaktionov et al., 1995) . Since repression of CDC25A and cell-cycle arrest induced by TGF-b1 also occur in cells lacking p15 gene it has been proposed that induction of P15 and repression of CDC25A are independent mechanisms mediating the inhibition of CDK4/6 activities (Iavarone and MassagueÂ , 1997) .
TGF-b1 is involved in a variety of cell functions including cell growth, cell dierentiation and cell ± cell or cell ± substrate interaction. Since TGF-b1 inhibits cell proliferation, the disruption of its signaling pathways could predispose to, or participate in the genesis of cancer. Alterations in single members of the TGF-b signaling pathways have been detected in a growing number of tumors. The TGF-b type II receptor is inactivated in a subset of gastrointestinal cancers (Akiyama et al., 1997; Markowitz et al., 1995; Souza et al., 1997) whereas it is overexpressed in human pancreatic cancer (Friess et al., 1993) . Although the TGF-b type I receptor can occasionally be altered in cancer cells (Kim et al., 1996a) little evidence is available to support an important role of TGF-b1 alterations in tumor progression. Moreover, inactivat-ing mutations in Smad4 and Smad2 genes have also been identi®ed. Smad4 (previously known as DPC4) (Derynck et al., 1996) , a tumor-suppressor gene located in chromosome 18q21.1, is inactivated in up to 40% of pancreatic cancers (Hahn et al., 1996a,b) and in a lower proportion of other tumors Kim et al., 1996b; Thiagalingam et al., 1996; Nagatake et al., 1996; Barret et al., 1996) . Smad2 (previously MADR-2) (Derynck et al., 1996) , also located at 18q21, has been found mutated in a proportion of colon cancer (Eppert et al., 1996) . Finally, while the incidence of P15 protein inactivation in primary pancreatic tumors remains unknown, p15 gene has been found altered in approximately 50% of pancreatic cancer cell lines (Naumann et al., 1996) .
Previous studies have shown that the use of pancreatic xenografts increases the sensitivity of detection of allelic losses and enables the identification of homozygous deletions (i.e., p16 and DPC4 genes) that otherwise would have not been detected in primary tumors (Caldas et al., 1994; Hahn et al., 1996b) . Although tumor cell selection probably occurs during in vivo perpetuation, orthotopic xenografts are close to their corresponding human pancreatic primary tumors and have proved useful for the study of those genetic events underlying distal dissemination (Reyes et al., 1996) .
Although scattered information is available, no studies have attempted to simultaneously analyse putative members of the TGF-b pathways in cancer cells. The aim of this study was to determine whether the TGF-b signaling pathways are disrupted in human pancreatic cancer. We have analysed the presence of concurrent alterations in members associated so far with these pathways (TGFb-RII, Smad2, Smad4, p15, and CDC25A) in a panel of orthotopic xenografts of human pancreatic carcinomas and their corresponding metastases, as well as in a series of pancreatic tumor cell lines. Here we show that TGF-b signaling pathways are disrupted in the majority of human pancreatic xenografts and their metastases. p15 gene is frequently inactivated in these tumors while Smad4 gene alterations are less common. Moreover, alterations in p15 and Smad4 genes may occur concomitantly and can be acquired during distal dissemination.
Results

Eect of TGF-b1 on DNA synthesis and proliferation
The eect of TGF-b1 on DNA replication was analysed in ®ve cell lines (NP9, NP18, NP29, NP31 and PANC-1). Cells were treated with a high dose of TGF-b1 (5 ng/ml) in a medium containing 10% FBS, or in serum-free conditions, and cell proliferation was assessed as described in Materials and methods. While TGF-b1 clearly inhibited proliferation of peripheral blood lymphocytes (data not shown), only a modest inhibition was observed in NP18, NP31 and PANC-1 cells (Table 1) . Lack of TGF-b1 response in NP9 and NP29 cells was observed both in serum-free conditions and in the presence of FBS (Table 1) . Interestingly, TGF-b1 induced changes in the morphology of NP31 cells (Table 1) in the absence of serum.
Genetic status and expression of TGF-bRII gene
The analysed repeats were normal in all xenografts and metastases (Table 2; Figure 1a ) and in all cell lines (Table 3) . RT ± PCR analysis showed that the TGFbRII transcript was present at high levels in all samples (Table 2; Figure 1b) . Moreover, all pancreatic xenografts and cell lines showed increased TGF-bR11 mRNA levels when compared to normal pancreatic tissues as assessed by Northern blotting (Figure 1c ). This overexpression was also observed in metastases obtained during in vivo dissemination in nude mice (Table 2; Figure 1c ).
Alterations and expression of Smad4 and Smad2 genes
Three types of genetic aberrations in the Smad4 gene were found: homozygous deletions, an abnormal SSCP pattern and loss of expression. STS markers showed that one (NP29) of the eight xenografts (Table 2; Figure  2a ), and two (NP29, BxPC3) of the seven cell lines (Table 3; Figure 2a ) harbored homozygous deletions encompassing the complete Smad4 locus. On the other hand, in xenograft NP18 (Figure 2b ) and its derived cell line (data not shown) an abnormal SSCP pattern was found when using primer set #2 (Table 4) . While an inactivating mutation or a polymorphism may be present in this fragment, it could not be detected by direct sequencing. RT ± PCR analysis con®rmed that full-length Smad4 transcripts were absent in samples containing homozygous deletions (Tables 2 and 3) . Finally, in three of the xenografts that retained all DNA markers analysed (NP9, NP40 and NP43), expression of Smad4 was progressively lost in advanced (more than 3) passages in nude mice (Figure 2c ). It is worth mentioning that NP9 cell line retained normal levels of Smad4 expression, whereas its xenograft of origin lost it in advanced passages. Quantitation of Smad4 transcripts by Northern blot analysis was not technically feasible suggesting that it might be expressed at very low levels.
One or more Smad4 STS markers were lost in all four metastases derived from NP37 tumor and in one liver metastasis from NP18 tumor (Table 2, Figure 3a ). Smad4 transcript was also absent in these samples (Figure 3 ). 
+ (7) (7) (7) + (7) (7) (7) +++ overexpression compared to normal pancreatic tissues. The intensity of normal pancreas was set as + and progressive increases were semiquantitatively scored, ++ to ++++. An abnormal SSCP pattern was observed using primer set #2 (Table 4) Finally, no point mutation or loss of expression was detected in the conserved domains of the Smad2 gene in any of the pancreatic tumors, metastases or cell lines analysed (Tables 2 and 3 ).
p15 gene aberrations
Four out of eight (50%) tumors have homozygous deletions of exons 1 and/or 2 of the p15 gene (NP31, NP37, NP43 and NP46). A point mutation in exon 1 was detected in NP40 tumor (Table 2 ; Figure 4a ); the signi®cance of this mutation is currently unknown since it is a single base substitution at nucleotide 71 just before the initiating codon (CGC(a)ATG to CGC(g)ATG) that does not aect RNA processing.
In the remaining three tumors (NP9, NP18 and NP29) homozygous deletion of exon 1 could be evidenced only in advanced passages. Thus, in contrast with the high degree of genetic stability regarding K-ras, p53, p16 genes status (Reyes et al., d When cell lines were inoculated in nude mice the resulting tumors showed the same homozygous deletion; wt, wild type allele;+, presence of RT ± PCR product or protein;7 absence of RT ± PCR product or protein; nd, not done repeats. Xenograft NP18 in dierent passages and their metastases showed a normal mobility pattern. Co-ampli®cation of mouse DNA occurred in (GT) 3 repeats (arrowhead) but SSCP analysis allowed identi®cation of the human fragment. (b and c) RT ± PCR and Northern blot analysis of total RNA from xenografts NP9, NP18 and NP40 in dierent passages and their metastases. All xenografts and their metastases showed increased TGFb-RII mRNA levels when compared with normal human pancreas. cDNA ampli®cation of the p53 gene and b-actin hybridization were used as a control for RNA quality. X#1, xenograft in passage 1; X#3, xenograft in passage 3; PM, peritoneal metastasis; LM, liver metastasis; Mouse Pa, normal mouse pancreas; Human Pa, normal human pancreas; M, DNA size marker Figure 2 Genetic aberrations and expression of the Smad4 gene in pancreatic xenografts and cell lines. (a) Xenograft NP29 and its corresponding cell line, as well as BxPC3 cell line, harbored homozygous deletion of DPC4 Exon 1, p128N21, c917-46-T7, and DPC4 Exon 11 STS markers. Co-ampli®cation of mouse DNA occurred in DPC4 Exon l and DPC4 Exon 11 markers, but the SSCP analysis allowed identi®cation of the human pattern. Deletions were absent in xenografts NP40 and NP43. (b) SSCP/ PCR analysis using primer set #2 (Table 3) showed an abnormal mobility pattern in xenograft NP18 (arrowhead). In contrast, NP9 and NP37 showed normal mobility patterns. (c) RT ± PCR ampli®cation of the whole coding region of the Smad4 gene. Expression of Smad4 gene was progressively lost in advanced passages of NP40 and NP43 xenografts. X#1 to 5, xenografts in passage 1 to 5; Line, NP29 cell line; H 2 O, unpurposefully added DNA. Other abbreviations as in Figure 1 Disruption of TGF-b signaling pathways in pancreatic cancer A Villanueva et al 1996) and allelotype (Hahn et al., 1995) , all pancreatic xenografts acquired p15 gene aberrations after several passages. All metastases derived from early passages of NP9 and NP18, which initially harbored a normal p15 gene, also acquired exon 1 homozygous deletions (Table 2 ; Figure 4a ). RT ± PCR analysis con®rmed that full-length p15 transcript was absent in these samples ( Figure 4b ). It is of interest that NP40 tumor (that initially had a point mutation before the initiating codon of exon 1), and NP43 and NP46 tumors (that initially had lost exon 2 of the p15 gene) acquired additional losses in exon 1 in advanced passages. Since p15 and p16 genes are located in the 9p21 region, P16 protein analysis, although not directly related to the TGF-signaling pathway, was also included to compare their expression pattern. It is noteworthy that in two tumors (NP18, NP37) p15 aberrations occurred independently of p16 gene status (Table 2) . 
(*) When these primers were used the whole coding region of the Smad4 gene (1659bp) was ampli®ed Four (NP31, MiaPaCa-2, PANC-1 and BxPC3) out of seven cell lines analysed harbored p15 gene homozygous deletions that involved both exons (Table 3) . Interestingly, an intact p15 gene was maintained in NP9 and NP18 cell lines after 60 passages (data not shown), whereas the corresponding perpetuated tumors progressively lost it.
Expression of CDC25A, P15 and P27
Since it has recently been reported that CDC25A is a positive cell cycle eector of the TGF-b pathways that is overexpressed in breast cancer (Iavarone and MassagueÂ , 1997; Galaktionov et al., 1995) , the levels of this protein were analysed by Western blotting. Expression of CDC25A protein was diminished in all xenografts and cell lines with respect to normal pancreas (Table 2; Figure 5a) ; decrease was more evident in tumors NP29, NP31, NP40 and NP46 (Table  2) . Since immunocytochemistry was not performed it cannot be ruled out that most of CDC25A expression in normal pancreas is present in acinar cells. It must be emphasized, however, that metastases derived from early passages of NP9 tumor, and all liver and some peritoneal metastases from NP18 tumor, showed additional decreases in CDC25A level (Figure 5b ) suggesting that cells containing low levels of CDC25A are selected for during in vivo dissemination. It is of note that levels of expression of CDC25A were independent on the status of p15 and Smad4 genes.
In agreement with genetic analysis, NP31, MiaPaCa-2, PANC-1 and BxPC3 cell lines have lost expression of P15 protein (Table 3 ; Figure 5a ). Finally, levels of P27 protein, also involved in the response to TGF-b1, were similar to those of normal pancreas in all cell lines analysed (Table 3) .
The modest inhibition of growth observed in NP18, NP31 and Panc-1 cells and morphological changes in NP31 cells, prompted us to analyse changes in P27 and CDC25A levels after TGF-b1 treatment. Synchronized serum-deprived cell cultures were treated for 24 h with 5 ng/ml of TGF-b1, and protein levels were analysed at dierent time intervals. As shown in Figure 5a , no eect of TGF-b1 on P27 or CDC25A expression was observed in any of the three cell lines, independently of the status of the TGF-b pathways. Similarly, expression of P15 was analysed in NP18 cell line. Results showed that P15 protein was not expressed in synchronized NP18 cells, even in the presence of TGF-b1 (Figure 5a ), suggesting that other pathways could regulate P15 expression in these cells.
Discussion
The presence of genetic aberrations and changes in protein expression in some of the known components of the TGF-b signaling pathways (TGF-bRII, Smad2, Smad4, p15 and CDC25A) have been simultaneously analysed in a panel of human orthotopic pancreatic xenografts and their corresponding metastases in nude mice, as well as in their derived pancreatic tumor cell lines. The results reveal that all xenografts and their derived metastases and cell lines (with exception of NP9 cell line) harbor alterations in at least one of the putative components of TGF-b pathways, mainly in p15 and Smad4 genes. Since growth of the NP9 cell line was not inhibited by TGF-b1, we conclude that all human pancreatic xenografts, metastases and cell lines analysed herein have non-functional TGF-b pathways. These results suggest that inactivation of TGF-b signaling pathways plays an important role in human pancreatic tumorigenesis.
Interestingly, two of the analysed putative components of the TGF-b pathways, p15 and Smad4 genes, are inactivated in the pancreatic tumors studied. p15 gene homozygous deletions that involve exons 1 and/ or 2, were found in 50% of early passages of pancreatic xenografts. The incidence of p15 aberrations in primary carcinomas of the human pancreas remains unknown. The use of xenografted tumors has allowed the detection of homozygous deletions that otherwise would not have been detected in primaries because of the presence of contaminating stromal cells. The identi®cation of p15 aberrations in early passages of the majority of samples suggests that p15 gene, a well-established cell cycle eector of TGF-b in some model systems, plays an important role in human pancreatic tumorigenesis. While it cannot be ruled out that p15-de®cient tumors may be overrepresented in our xenografts, it is likely that its inactivation may be present in a signi®cant proportion of primary tumors. The identi®cation of p15 aberrations in early passages of the majority of samples suggests that p15 gene, a well-established cell cycle eector of TGF-b in some model systems, plays an important role in human pancreatic tumorigenesis. While it cannot be ruled out that p15-de®cient tumors may be overrepresented in our xenografts, it is likely that its inactivation may be present in a signi®cant proportion of primary tumors. Alterations in the p15 gene might be responsible for the resistance to TGF-b inhibitory eects in a high proportion of pancreatic tumors. It must be emphasized that p15 is a universal cyclin/cdk inhibitor and that could also be the cellcycle eector of other signaling pathways. Both p15 and p16 genes are located in the 9p21 region and losses of this region occur at high frequency in pancreatic carcinomas (Reyes et al., 1996; Hahn et al., 1995) . Co-deletions of p15 and p16 genes have been previously reported in pancreatic cancer cell lines and it has been suggested that p16 is more likely the target gene in this region (Naumann et al., 1996; Huang et al., 1996) . In agreement with other studies (Caldas et al., 1994) , we showed that the majority of pancreatic xenografts contained p16 genetic aberrations (Reyes et al., 1996) . Interestingly, the concurrent analysis of p15 and p16 genes in the xenografts demonstrates that p15 gene aberrations occur independently of p16 status, and suggests that p15 may be also an important target gene in the 9p21 region.
Homozygous deletions and inactivating intragenic mutations in the Smad4 gene have been previously reported in approximately 40% of pancreatic xenografts (Hahn et al., 1996a,b) , and in a lower proportion of tumors arising from other organs Kim et al., 1996b; Thiagalingam et al., 1996; Nagatake et al., 1996; Barret et al., 1996) . We have detected a homozygous deletion in the Smad4 gene in only one of the eight xenografts suggesting that these alterations may not be as frequent as previously reported. It could be speculated that the geographical dierences could account for these dierences as has been previously shown for ras mutations (Scarpa et al, 1994) . On the other hand, Smad2 gene was not altered in pancreatic tumorigenesis, in contrast with the presence of Smad2 gene mutations in sporadic colon tumors (Eppert et al., 1996) . The dierential pattern of genetic aberrations in Smad4 and Smad2 may re¯ect some degree of tissuespeci®city among SMAD proteins.
Orthotopic implantation of human pancreatic cancers in the nude mice facilitates the reproduction, in the experimental animal, of their distal dissemination patterns. Using this model system we have shown that p15 and Smad4 genes aberrations accumulate during distal dissemination of early passages of orthotopic xenografts indicating that these alterations may confer selective growth advantage in vivo. Previously we showed that ras and p53 gene mutations but not p16 alterations are acquired during dissemination (Reyes et al., 1996) . Altogether these ®ndings reinforce the role of p15 and Smad4 genetic alterations in the more advanced stages of human pancreatic tumorigenesis. The fact that concomitant inactivation of both genes have been found in experimental metastases suggests that P15 and SMAD4 proteins may play complementary roles in the regulation of human pancreatic cancer cell growth, and re¯ects the complexity of the TGF-b signaling pathways.
In previous reports it has been shown that human pancreatic xenografts show a high degree of genetic stability regarding K-ras, p53, p16 genes status (Reyes et al., 1996) . In contrast, additional p15 and/or Smad4 genes alterations accumulate in advanced passages of xenografts. P15 is absent from all xenografts in their advanced passages. It is noteworthy that additional exon 1 losses can occur in the presence of previous exon 2 losses. This might re¯ect the loss of p10, a recently identi®ed transcript that shares exon 1 with p15 gene (Tsubari et al., 1997) , similar to what has been described for the INK4a locus (Serrano et al., 1996) . Finally, loss of expression, a novel mechanism of Smad4 inactivation in vivo, has been observed in advanced passages of several of our pancreatic xenografts lines suggesting that Smad4 gene may be rendered inactive by transcriptional regulation or by RNA instability. Finally, it should be noted that p15 and Smad4 genes are simultaneously inactivated in the majority (5 out of 8) of advanced passages of our orthotopic pancreatic xenografts reinforcing the putative complementary roles of both proteins.
The pattern of genetic alterations present in established tumor cell lines may dier from primaries or perpetuated tumors regarding speci®c genes (i.e. p16 or p53) (Huang et al., 1996) . The incidence of Smad4 gene alterations in the panel of cell lines analysed (3 of 7) is higher than in xenografts indicating that these alterations may be selected for during in vitro immortalization. On the other hand, the percentage of alterations in p15 gene in our tumor cell lines is somewhat lower than in the corresponding xenografts (43%) suggesting that p15 loss does not confer selective growth advantage in vitro.
TGF-b has been also shown to inhibit CDC25A, whose main action is to activate CDK4 by desphosphorylating a speci®c site of this kinase (Galaktionov and Beach., 1991) . Previously, it has been reported that CDC25A may act as an oncogene when overexpressed (Galaktionov et al., 1995) . Surprisingly, expression of CDC25A was found decreased in all xenografts and in some cell lines analysed when compared to normal human pancreas. Moreover, cells with low CDC25A levels were selected for during in vivo tumor perpetuation and dissemination. Since decreased levels of CDC25A should lead to a reduced activity of CDK4, the signi®cance of this ®nding is not clear. One can speculate that this may re¯ect a cellular response to hyperproliferation with the aim of braking the cell cycle. If this was the case, CDC25A could be a relevant component of a cell cycle checkpoint involved in the regulation of CDKs activity.
In agreement with previous reports (Friess et al., 1993; Baldwin and Korc, 1993) , TGF-bRII is consistently overexpressed in our pancreatic xenografts and cell lines. Moreover, overexpression is maintained during distal dissemination. Since it always occurs in the presence of aberrations in Smad4 and/or p15 genes (with the possible exception of NP9 cell line), TGF-bRII overexpression might be a cellular escape from hyperproliferation, with the aim of arresting the cell cycle by activation of the TGF-b inhibitory pathways. Alternatively, TGF-bRII could be involved in signaling pathways other than those involving SMAD4 and P15 proteins, which could confer selective growth advantage to pancreatic tumor cells.
The ®nding of unaltered components in the NP9 cell line, refractory to TGF-b treatment, could re¯ect the limited sensitivity of the experimental procedures utilized. Alternatively, it may also indicate that, other known members of the TGF-b signaling pathways (i.e. TGF-bRI) could be altered, although alterations in these genes are not common in cancer cells (Kim et al., 1996) . The recent description of new Smad genes, that are apparently not mutated in pancreatic cancer (Riggins et al., 1997) , emphasizes the increasing complexity of these pathways and add new candidate genes that could be altered. In conclusion, results reported herein indicate that the TGF-b signaling pathways are disrupted in human pancreatic cancer cells. Disruption mainly occurs by inactivation of p15 and Smad4 genes, suggesting that alterations of these genes may be critical for human pancreatic tumorigenesis and dissemination to occur. Paradoxical changes in the expression of TGF-bRII and CDC25A have been detected, although its meaning remains unclear.
Materials and methods
Human pancreatic cancer xenografts and cell lines
Eight pancreatic cancer xenografts orthotopically implanted in nude mice, that retained the histological appearance of the primary tumors and a high degree of genetic stability (Reyes et al., 1996) , were analysed in dierent passages. A total of 25 metastases from dierent locations (Table 2) obtained during distal dissemination of four perpetuated tumors were also analysed (Reyes et al., 1996) .
Human pancreatic tumor cell lines Panc-1. MiaPaCa2, BxPC3 were obtained from the American type Culture Collection (Rockville, MD, USA). Human pancreatic tumor cell lines NP9, NP29, NP31 and NP18 were established in our laboratory from perpetuated xenografts orthotopically implanted in nude mice (GarcõÂ a et al., submitted) In vitro proliferation assays Thymidine incorporation In vitro studies were performed using exponentially growing monolayers of NP9, NP18, NP29, NP31 and Panc-1 cells. Peripheral blood lymphocytes were used as a control. Cells were grown in 6-well tissue plates at an initial seeding density of 30 000 cells/ well in culture medium (RPMI or DME : Ham's F12) containing 10% FBS for 48 h. After this period of preincubation, TGF-b1 (5 ng/ml) was added to the medium in the presence or absence of 10% FBS for 48 h and 72 h. At the end of this period cells were incubated for 1 h with [ 3 H]thymidine (1 mCi of 50 Ci/mmol) (Amersham International, Buckinghamshire, UK) and the incorporation into acid-insoluble fraction was assayed .
MTT Cells (15 000 ± 30 000 per well) were seeded into 96-well plates and grown for 48 h in medium containing 10% FBS. Cells were then treated as described above. Following an incubation period of 72 ± 96 h at 378C, 10 ml of MTT (Sigma, St. Louis) (10 ng/ml) were added to each well for 4 h. Optical density was measured at 550 nm using an ELISA microplate reader (Behring EL311). Data were expressed as percentage of stimulated versus control cells .
Analysis of TGF-bRII gene
Point mutations Two segments of the TGF-bRII gene, the (A) 10 region spanning codons 97 ± 153 and the (GT) 3 region extending from codons 510 ± 559, that comprise the majority of reported somatic mutations of this gene were analysed (Akiyama et al., 1997) . Electrophoresis was carried out in a 8% polyacrylamide/10% glycerol nondenaturing sequencing gel at room temperature under 7 W for 12 h. When concomitant mouse DNA ampli®cation occurred, SSCP analysis allowed the characterization of the human fragments.
RT ± PCR and Northern blot analysis Total RNA was extracted from cell pellets and tissues by a single-step method (Chomczyski and Sachi, 1987) . Two mg of total RNA was reverse transcribed to CDNA as previously described (Mato et al., 1993) and a 1386 bp fragment, encompassing codons 97 ± 559, was ampli®ed using speci®c primers (Table 4) . Northern blot was used to analyse cell lines, pancreatic xenografts, and normal tissues. Approximately 10 mg of total RNA was electrophoresed in 1.2% agarose gels containing formaldehyde and blotted to nylon membranes (Hybond N + , Amersham International, Buckinghamshire, UK) following manufacturer's instructions. The 1386 bp fragment generated by RT ± PCR was used as a probe. Membranes were hybridized overnight, and washed under stringent conditions (658C and 0.1% SSC/ 0.1% SDS). Internal control for amount of RNA in the ®lter was obtained by hybridization with a human cDNA b-actin probe.
Detection of Smad4 gene aberrations
Analysis of homozygous deletions of the Smad4 gene and neighboring regions Six sequence-tagged site (STS) markers (Hahn et al., 1996a,b) , that map centromeric to the DCC gene, were used (Hahn et al., 1996b) : y747A6R, DPC4Exon 1, c917-46-T7, p128-N21, DPC4Exon 11, p0630-HS-T7. All STSs were ampli®ed using 50 ng of genomic DNA in the presence of radioactive nucleotide ([ 32 P]CTP, 2 mCi/PCR tube) in a mixture containing PCR buer [10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl 2 ,50 mM KCl, 0.01 % (w/v) gelatine], 100 mM of each dNTPs, 1 mM of each primer, and 1 unit of Taq DNA polymerase (LifeTechnologies, Gaithersburg, MD, USA) in a ®nal volume of 20 ml. Annealing temperature, extension time, and concentration of MgCl 2 were optimized for each primer set. All reactions were performed in a Hybaid thermal cycler for 35 cycles. A homozygous deletion was de®ned by the absence of PCR product in three independent experiments. DNA quality was tested by amplifying a 1.2 kb fragment of the p53 gene. In all experiments, controls for DNA contamination were included every other sample. Co-ampli®cation of mouse DNA was evidenced with markers DPC4 Exon 1 and DPC4 Exon 11; SSCP analysis allowed characterization of the human PCR product.
RT ± PCR assay and mutation analysis The whole coding region of the Smad4 gene was ampli®ed in ®ve overlapped reactions. All primers used for PCR ampli®cation were designed based on the published cDNA sequence (Hahn et al., 1996b) (Table 4 ). Five ml of the RT reaction was added to a mixture containing PCR buer, 0.3 mM of each dNTPs, 2.5 mM MgCl 2 , 1 mM of primers and 1.5 U of Taq polymerase in the presence of radioactive nucleotide ([ 32 P]dCTP, 2 mCi/PCR tube). The reaction was performed in a Perkin-Elmer thermal cycler for 30 cycles (578C, 1 min; 728C, 2 min; 948C, 1 min) in a ®nal volume of 30 ml. No PCR product was obtained when genomic DNA was used as template. P53 cDNA gene ampli®cation was performed to test the eciency of RT reaction. Mouse RNA was included in all experiments to rule out contamination by nude mouse products. All reactions were performed independently at least three times using dierent RNA isolates. The identity of the ampli®ed fragments was con®rmed by cycle sequencing using the AmpliCycle Sequencing Kit (Perkin Elmer, Branchburg, NJ, USA) following manufacturer's directions. Mutational analysis of the Smad4 gene was performed by means of the SSCP method. Electrophoresis was carried out in a 7% polyacrylamide/10% glycerol non-denaturing sequencing gel at room temperature under 5 W for 12 ± 15 h, and at 48C under 30 W for 7 ± 10 h. When concomitant mouse DNA ampli®cation occurred, SSCP analysis allowed the characterization of the human fragment. Northern blot analysis using total cellular RNA was also attempted following essentially the same protocol described for TGFbRII analysis. Probes encompassing the whole coding region of the Smad4 gene and the dierent ampli®ed fragments described above were utilized.
Analysis of Smad2 gene cDNA was obtained as described above. The coding regions of the conserved domains of SMAD2 protein were ampli®ed using primers previously reported (Eppert et al., 1996) . Annealing temperature, extension time, and concentration of MgCl 2 were optimized for each primer set. Mutational analysis was performed following essentially the same protocol used for the Smad4 gene analysis.
Detection of p15 gene aberrations
Mutational analysis One hundred 7200 ng of genomic DNA was used to amplify exons 1 and 2 of the p15 gene in three independent PCR reactions using human intronic primers Jen et al., 1994) . SSCP analysis was essentially performed as described above with the only exception that electrophoresis was carried out at room temperature under 7 W for 18 h using radioactive nucleotide or silver staining. Identity of the fragments was con®rmed by cycle sequencing adding 10% DMSO to the sequencing mixture.
Allelic losses They were analysed by means of two microsatellite length polymorphism (D9S171, IFNA) as described (Reyes et al., 1996) . The products were separated on a 6% polyacrylamide/8 M urea gel, and autoradiography was performed.
RT ± PCR The levels of p15 mRNA were analysed by means of RT ± PCR using speci®c exonic primers (Table 4) .
Western blotting
Expression of P15, P16, P27 and CDC25A proteins was analysed by Western blotting in pancreatic xenografts, metastases and cells growing asynchronously. Samples were frozen, lysed in 80 mM Tris-HCl (pH 6.8) containing 2% SDS, sonicated and ®nally resuspended in Laemmii buer. Fifty mg of protein were then electrophoresed using 10% (P27, CDC25A) or 15% (P15, P16) SDS-polyacrylamide gel and transferred onto Immobilon P membranes (Millipore, Bedford, MA, USA). Western blotting was performed using speci®c polyclonal antibodies against P15 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 200); P16 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 200); P27 (a kind gift of Dr MassagueÂ , New York, USA; dilution 1 : 100); and CDC25A (144, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 2000). Additional experiments were performed in cell lines NP18, NP31 and PANC-1 that showed a modest inhibitory response to TGF-b1 or morphological changes in the presence of TGF-b1. Cells were synchronized in serum-deprived media for 72 h and then exposed to TGF-b1 (5 ng/ml) (Calbiochem, Cambridge, MA, USA). Proteins were analysed at dierent time intervals (0, 6, and 12 h) after exposure to TGF-b1.
Abbreviations TGF-bRII Transforming Growth Factor b receptor type II; LOH, loss of heterozygosity; SSCP, single strand conformation polymorphism; STS, Sequence-tagged site.
